https://doi.org/10.55788/0c07fdc5
Tremendous progress in applying AI to cardiology has recently been made. In that context, Dr David Ouyang (Cedars-Sinai Smidt Heart Institute, CA, USA) reported the findings of the EchoNet-RCT (NCT05140642) [1].
The researchers measured how often cardiologists changed the initial assessment by AI compared with how often they changed the initial assessment by sonographer. Researchers randomly assigned transthoracic echocardiograms performed on adults for any clinical indication to either AI initial assessment or sonographer initial assessment, after which blinded cardiologists reviewed the assessment and provided a final report of LVEF. The AI element made use of a deep learning algorithm called EchoNet-Dynamic, which was trained on echocardiogram videos to assess cardiac function and was previously shown to assess LVEF, using information across multiple cardiac cycles to minimise error and produce consistent results [2]. The primary endpoint was the frequency of a >5% change in LVEF between the initial assessment (AI or sonographer) and the final cardiologist report. The trial was designed to test for non-inferiority, with a secondary objective of testing for superiority.
Transthoracic echocardiograms (n=3,495) were performed on adults for any clinical indication, and then randomised for LVEF assessment to either AI or an experienced sonographer (results summarised in Table). The proportion of assessments that was substantially changed was 16.8% in the AI group and 27.2% in the sonographer group (difference -10.4%, 95% CI -13.2% to -7.7%; P<0.001 for non-inferiority, P<0.001 for superiority). The safety endpoint was the difference between the final cardiologist report and a historical cardiologist report. The mean absolute difference was 6.3% in the AI group and 7.2% in the sonographer group (difference -0.96%; 95% CI -1.34% to -0.54%; P<0.001 for superiority).
Table: EchoNet trial results [1]

In conclusion, Dr Ouyang said: “We were initially quite conservative. This was built as a non-inferiority study, but it actually met that endpoint as well as the endpoint of superiority, so we were pleasantly surprised to see that it was able to work so well. This shows that AI in certain cases is ready for primetime.”
- Ouyang D, et al. EchoNet-RCT - Safety and Efficacy Study of AI LVEF. Hot Line Session 3, ESC Congress 2022, Barcelona, Spain, 26–29 August.
- Ouyang D, et al. Nature. 2020;580(7802):252–256.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« AI-enhanced echography supports aortic stenosis patients Next Article
ENTRIGUE: Subcutaneous pegozafermin in severe hypertriglyceridaemia »
« AI-enhanced echography supports aortic stenosis patients Next Article
ENTRIGUE: Subcutaneous pegozafermin in severe hypertriglyceridaemia »
Table of Contents: ESC 2022
Featured articles
ESC Clinical Practice Guidelines
Prevention of VT and sudden cardiac death: the new recommendations
New and first ESC cardio-oncology guideline
The 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension
Cardiovascular assessment and management of patients undergoing non-cardiac surgery
Heart Failure
Old dogs, new tricks: Acetazolamide plus loop diuretics improves decongestion
No effect of neprilysin inhibition on cognition
Dapagliflozin DELIVERs for HFmrEF/HFpEF
Meta-analysis of DELIVER and EMPEROR-Preserved
Anticoagulation
Rheumatic heart disease-associated AF: standard-of-care holds ground
New anticoagulant safe and maybe effective: PACIFIC-AMI and PACIFIC-Stroke outcomes
AXIOMATIC-SSP: Reducing risk of ischaemic stroke with factor XIa inhibition?
Evolving evidence for P2Y12 inhibition in chronic coronary syndromes: PANTHER
Prevention
Danish study suggests starting CVD screening before age 70
Polypill SECUREs win in secondary prevention in elderly
Long-term therapy with evolocumab associated with lower CV mortality
ARBs + beta-blockers may delay Marfan syndrome aortic root replacement
ENTRIGUE: Subcutaneous pegozafermin in severe hypertriglyceridaemia
Artificial Intelligence & Digital Health – What Is New
First RCT evidence for use of AI in daily practice
AI-enhanced echography supports aortic stenosis patients
Ischaemia
Medical therapy versus PCI for ischaemic cardiomyopathy
Allopurinol disappoints in ALL-HEART
Conservative or invasive management for high-risk kidney disease patients with ischaemia?
Genotype-guided antiplatelet therapy in patients receiving PCI
Other HOTLINE Sessions
BOXing out oxygen and blood pressure targets
Coronary CT angiography diagnostics compared head-to-head
High-dose influenza vaccine: mortality benefit?
FFR-guided decision-making in patients with AMI and multivessel disease
Related Articles

October 27, 2022
First RCT evidence for use of AI in daily practice
October 27, 2022
Genotype-guided antiplatelet therapy in patients receiving PCI
October 27, 2022
Take hypertension medication anyTIME
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com